Aimmune Therapeutics Inc. (AIMT)

18.52
0.03 0.16
NASDAQ : Health Technology
Prev Close 18.55
Open 18.50
Day Low/High 18.38 / 18.56
52 Wk Low/High 16.95 / 36.12
Volume 7.60K
Avg Volume 504.80K
Exchange NASDAQ
Shares Outstanding 62.49M
Market Cap 1.15B
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aimmune Submits Marketing Authorization Application To European Medicines Agency For AR101 For Peanut Allergy

Aimmune Submits Marketing Authorization Application To European Medicines Agency For AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for...

Aimmune To Present At The JMP Securities Life Sciences Conference

Aimmune To Present At The JMP Securities Life Sciences Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.

Aimmune Therapeutics Discusses AR101's Cost-Effectiveness And Demonstrated Clinical Benefits At ICER Meeting

Aimmune Therapeutics Discusses AR101's Cost-Effectiveness And Demonstrated Clinical Benefits At ICER Meeting

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at the Institute for Clinical and Economic Review's (ICER) Public Meeting reviewing the effectiveness and value...

Aimmune To Participate In The Goldman Sachs 40th Annual Healthcare Conference

Aimmune To Participate In The Goldman Sachs 40th Annual Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Sachs 40 th...

Stocks Take Flight on Dovish Fed Comments

Stocks Take Flight on Dovish Fed Comments

Market players are trying to decipher Fed Chair Powell's latest words.

Data From Two Studies Confirm Quality Of Life And Psychosocial Burden Of Living With Peanut Allergy

Data From Two Studies Confirm Quality Of Life And Psychosocial Burden Of Living With Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced new data from two studies that assessed the psychosocial burden of living with peanut allergy.

New Data From Phase 3 PALISADE Follow-on Study Of AR101 For Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year

New Data From Phase 3 PALISADE Follow-on Study Of AR101 For Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced results from ARC004, an open-label, rollover study of the landmark Phase 3 PALISADE trial, which showed that...

Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety And Efficacy Of AR101 In Children And Adolescents With Peanut Allergy

Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety And Efficacy Of AR101 In Children And Adolescents With Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today presented topline results from the pivotal European Phase 3 ARTEMIS clinical trial, which it previously announced had...

First Week Of July 19th Options Trading For Aimmune Therapeutics (AIMT)

First Week Of July 19th Options Trading For Aimmune Therapeutics (AIMT)

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the July 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new July 19th contracts and identified one put and one call contract of particular interest.

Aimmune To Present AR101 Data At European Academy Of Allergy And Clinical Immunology 2019 Congress

Aimmune To Present AR101 Data At European Academy Of Allergy And Clinical Immunology 2019 Congress

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will present AR101 and patient quality of life data at the European Academy of Allergy and Clinical...

New Study Shows More Than Half Of Teens With Peanut Allergy Visited The E.R., More Than One-Third Required Hospitalization Due To Accidental Exposure To Peanut

New Study Shows More Than Half Of Teens With Peanut Allergy Visited The E.R., More Than One-Third Required Hospitalization Due To Accidental Exposure To Peanut

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced results of a new study of U.

Aimmune To Present At RBC Capital Markets Global Healthcare Conference

Aimmune To Present At RBC Capital Markets Global Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the RBC Capital Markets Global Healthcare...

Aimmune Announces U.S. FDA Advisory Committee Meeting Date For AR101 For Peanut Allergy

Aimmune Announces U.S. FDA Advisory Committee Meeting Date For AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.

Aimmune Therapeutics Announces First Quarter 2019 Financial Results And Provides Operational Highlights

Aimmune Therapeutics Announces First Quarter 2019 Financial Results And Provides Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter ended March 31, 2019.

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss First Quarter 2019 Financial Results And Recent Operational Highlights

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss First Quarter 2019 Financial Results And Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Wednesday, May 8, 2019, at 4:30 p.

Giddiness Eludes

No indicators to support giddiness as breadth improves, small caps join the party, and number of new highs looks pretty small.

Qualcomm/Apple, 'Medicare for All' Talk Ignite Extreme Market Rotation

Qualcomm/Apple, 'Medicare for All' Talk Ignite Extreme Market Rotation

There is a bloodbath of selling in medical-related names and severe pressure on cloud-related stocks that have been momentum favorites.

Aimmune Therapeutics To Present At 18th Annual Needham & Company Healthcare Conference

Aimmune Therapeutics To Present At 18th Annual Needham & Company Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

European Phase 3 Trial Of Aimmune Therapeutics' AR101 Meets Primary Endpoint

European Phase 3 Trial Of Aimmune Therapeutics' AR101 Meets Primary Endpoint

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its phase 3 European clinical trial of AR101 for the treatment of peanut allergy, known as ARTEMIS (...

First Week Of May 17th Options Trading For Aimmune Therapeutics (AIMT)

First Week Of May 17th Options Trading For Aimmune Therapeutics (AIMT)

Investors in Aimmune Therapeutics Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

U.S. FDA Accepts BLA Filing Of Aimmune Therapeutics' AR101 For Peanut Allergy

U.S. FDA Accepts BLA Filing Of Aimmune Therapeutics' AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that the Biologics License Application (BLA) for AR101 has been accepted for review by the U.

Aimmune Therapeutics To Participate In Three Investor Conferences In March

Aimmune Therapeutics To Participate In Three Investor Conferences In March

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor conferences...

Aimmune Therapeutics Announces Fourth Quarter And Full Year 2018 Financial Results And Provides Recent Operational Highlights

Aimmune Therapeutics Announces Fourth Quarter And Full Year 2018 Financial Results And Provides Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year 2018.

Aimmune Therapeutics Presents New AR101 Data At AAAAI, Including Demonstrated Reduction In Accidental Exposures To Peanut Requiring Treatment

Aimmune Therapeutics Presents New AR101 Data At AAAAI, Including Demonstrated Reduction In Accidental Exposures To Peanut Requiring Treatment

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented new data on AR101, its investigational treatment for peanut allergy, at the American Academy of...

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss Fourth Quarter And Full-Year 2018 Financial Results And Recent Operational Highlights

Aimmune Therapeutics To Host Conference Call And Webcast To Discuss Fourth Quarter And Full-Year 2018 Financial Results And Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.

Trading Notes for Select Stocks

Trading Notes for Select Stocks

Here's my take on a list of stocks I've been watching.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.